siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells.

Razi Soofiyani, Saiedeh; Mohammad Hoseini, Akbar; Mohammadi, Ali; Khaze Shahgoli, Vahid; Baradaran, Behzad; Hejazi, Mohammad Saeid

Razi Soofiyani, Saiedeh; Mohammad Hoseini, Akbar; Mohammadi, Ali; Khaze Shahgoli, Vahid; Baradaran, Behzad; Hejazi, Mohammad Saeid.

Afiliação

Razi Soofiyani S; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammad Hoseini A; Department of Molecular Medicine, Faculty of Advanced Biomedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammadi A; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Khaze Shahgoli V; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Baradaran B; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Hejazi MS; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Adv Pharm Bull ; 7(4): 637-643, 2017 Dec.

Article em En | MEDLINE | ID: mdl-29399554

Palavras-chave

CIP2A; Docetaxel; Prostate cancer; siRNA

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Prostata Base de dados: MEDLINE Idioma: En Revista: Adv Pharm Bull Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Irã

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google